Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Director Declaration

9 Jun 2009 11:36

RNS Number : 5979T
e-Therapeutics plc
09 June 2009
 



e-Therapeutics plc

('ETX' or 'the Company')

CHANGE TO DIRECTOR'S DETAILS

 

Pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies, Dr Royston Drucker (Chief Medical Officer of the Company) has become aware that  Technomark Consulting Services Limited, a company of which he was a non-executive director until his resignation on 08 June 2007, entered a company voluntary arrangement on 17 March 2008. 

Dr Royston Drucker has no further details at this time.

 

For further information please contact:

e-Therapeutics plc

www.etherapeutics.co.uk

Malcolm Young

+44 (0) 191 233 1317

Nominated Adviser

WH Ireland Limited

+44 (0) 161 832 2174

Katy Mitchell

Broker

Cornhill Asset Management

+44 (0) 207 645 8327

Tom Whitehead

Media enquiries

Abchurch

Heather Salmond

+44 (0) 207 398 7704

Stephanie Cuthbert

+44 (0) 207 398 7718

Simone Alves

+44 (0) 207 398 7728

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDNUUUPWQUPBGUB
Date   Source Headline
9th May 20247:00 amRNSCancellation - e-Therapeutics Plc
8th May 20247:00 amRNSLast Day of Dealings on AIM
3rd May 20246:00 pmRNSe-therapeutics
29th Apr 20242:09 pmRNSResult of General Meeting
10th Apr 20247:00 amRNSProposed Fundraise of £28.9m and Cancellation
31st Jan 20244:30 pmRNSTotal Voting Rights
24th Jan 202410:04 amRNSExercise of Options and Issue of Equity
16th Jan 20247:00 amRNSBusiness Update
9th Jan 20244:04 pmRNSDirector Dealing and Issue of Equity
27th Dec 20237:00 amRNSUpdate on OTCQX Market Listing
13th Nov 20239:05 amEQSEdison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
2nd Nov 20237:00 amRNSStrategic RWE collaboration with Arcturis
26th Oct 20237:38 amRNSInterim results for the six months to 31 July 2023
19th Oct 20239:54 amRNSNotice of Interim Results
20th Sep 20237:00 amRNSSenior Management Update
7th Sep 202311:47 amRNSExercise of Options and Issue of Equity
31st Jul 20234:30 pmRNSTotal Voting Rights
18th Jul 20234:20 pmRNSResult of Annual General Meeting
6th Jul 20235:27 pmRNSDirector Dealing and Issue of Equity
30th Jun 20237:00 amRNSInvestor Presentation
26th Jun 20237:00 amRNSNotice of Investor Presentation
11th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
4th May 20237:00 amRNSFinal results for the year ended 31 January 2023
28th Apr 20234:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSNotification of Full Year Results Date
28th Mar 20233:57 pmRNSExercise of Options and Issue of Equity
21st Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 202310:19 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSFiling of four patent applications
31st Jan 20237:00 amRNSTotal Voting Rights
4th Jan 20233:15 pmRNSDirector Dealing and Issue of Equity
29th Dec 20224:40 pmRNSSecond Price Monitoring Extn
29th Dec 20224:35 pmRNSPrice Monitoring Extension
20th Dec 20224:35 pmRNSPrice Monitoring Extension
31st Oct 20227:00 amRNSTotal Voting Rights
12th Oct 20223:12 pmRNSHolding(s) in Company
11th Oct 202210:42 amRNSHolding(s) in Company
10th Oct 20228:03 amRNSHolding(s) in Company
30th Sep 20227:00 amRNSInterim results for the six months to 31 July 2022
30th Sep 20227:00 amRNSFundraise of £13.5 million by way of Subscription
26th Sep 20224:40 pmRNSSecond Price Monitoring Extn
26th Sep 20224:36 pmRNSPrice Monitoring Extension
1st Aug 20227:00 amRNSFiling of eight patent applications
29th Jul 20227:00 amRNSTotal Voting Rights
20th Jul 202210:39 amRNSResult of Annual General Meeting
6th Jul 20227:00 amRNSNotice to Shareholders - AGM Virtual Access
5th Jul 20227:00 amRNSDirector Dealing and Issue of Equity
17th May 20227:00 amRNSNotice of AGM and Posting of Annual Report
4th May 20227:00 amRNSFinal results for the year ended 31 January 2022
27th Apr 20227:00 amRNSNotification of Full Year Results Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.